Recent advances in HDAC-based multi-target inhibitors

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Oncology

Background:

• Histone deacetylase (HDAC) inhibitors are approved for hematologic malignancies.
• Their use in solid tumors is limited by efficacy, resistance, and toxicity.
• Multi-target inhibitors present a strategy to overcome these limitations.

Purpose of the Study:

• To review recent advancements in HDAC-based multi-target compounds.
• To emphasize target selection, molecular design, and structure-activity relationships.
• To highlight biological activities and therapeutic potential.

Main Methods:

• Literature review of recent studies on HDAC-based multi-target compounds.
• Analysis of target selection and molecular design strategies.
• Evaluation of structure-activity relationships and biological data.

Main Results:

• Dual-target HDAC inhibitors demonstrate enhanced synergistic effects.
• These compounds show potential in overcoming drug resistance and reducing toxicity.
• Successful examples of multi-target HDAC inhibitors are discussed.

Conclusions:

• HDAC-based multi-target compounds offer a promising approach for solid tumor treatment.
• Further research into molecular design and biological evaluation is warranted.
• These inhibitors hold potential for treating tumors, neurological, and inflammatory diseases.